GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tarsus Pharmaceuticals Inc (NAS:TARS) » Definitions » PS Ratio

Tarsus Pharmaceuticals (Tarsus Pharmaceuticals) PS Ratio : 31.24 (As of May. 17, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Tarsus Pharmaceuticals PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Tarsus Pharmaceuticals's share price is $38.58. Tarsus Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $1.24. Hence, Tarsus Pharmaceuticals's PS Ratio for today is 31.24.

The historical rank and industry rank for Tarsus Pharmaceuticals's PS Ratio or its related term are showing as below:

TARS' s PS Ratio Range Over the Past 10 Years
Min: 5.55   Med: 19.8   Max: 67.67
Current: 31.17

During the past 6 years, Tarsus Pharmaceuticals's highest PS Ratio was 67.67. The lowest was 5.55. And the median was 19.80.

TARS's PS Ratio is ranked worse than
72.8% of 1000 companies
in the Biotechnology industry
Industry Median: 9.155 vs TARS: 31.17

Tarsus Pharmaceuticals's Revenue per Sharefor the three months ended in Mar. 2024 was $0.78. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $1.24.

During the past 12 months, the average Revenue per Share Growth Rate of Tarsus Pharmaceuticals was 12.80% per year.

Back to Basics: PS Ratio


Tarsus Pharmaceuticals PS Ratio Historical Data

The historical data trend for Tarsus Pharmaceuticals's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tarsus Pharmaceuticals PS Ratio Chart

Tarsus Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial - - 8.11 13.98 34.09

Tarsus Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.48 38.69 33.66 34.09 29.43

Competitive Comparison of Tarsus Pharmaceuticals's PS Ratio

For the Biotechnology subindustry, Tarsus Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tarsus Pharmaceuticals's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tarsus Pharmaceuticals's PS Ratio distribution charts can be found below:

* The bar in red indicates where Tarsus Pharmaceuticals's PS Ratio falls into.



Tarsus Pharmaceuticals PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Tarsus Pharmaceuticals's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=38.58/1.235
=31.24

Tarsus Pharmaceuticals's Share Price of today is $38.58.
Tarsus Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.24.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Tarsus Pharmaceuticals  (NAS:TARS) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Tarsus Pharmaceuticals PS Ratio Related Terms

Thank you for viewing the detailed overview of Tarsus Pharmaceuticals's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Tarsus Pharmaceuticals (Tarsus Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
15440 Laguna Canyon Road, Suite 160, Irvine, CA, USA, 92618
Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's lead candidate TP-03 is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
Executives
Bobak R. Azamian director, 10 percent owner, officer: President and CEO 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Jose M. Trevejo officer: Chief Medical Officer C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Andrew D. Goldberg director 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Dianne C. Whitfield officer: Chief Human Resources Officer 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Bryan Wahl officer: General Counsel 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Elizabeth Yeu Lin director 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA 92630
Aziz Mottiwala officer: Chief Commercial Officer 233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Jeffrey S Farrow officer: See Remarks TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Leonard M. Greenstein officer: Chief Financial Officer 24562 BELGREEN PLACE, LAKE FOREST CA 92630
Seshadri Neervannan officer: Chief Operating Officer 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Mark J. Holdbrook officer: V.P., Clinical Affairs 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Scott W Morrison director C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT SUITE 101, SOUTH SAN FRANCISCO CA 94080
Vivo Capital Fund Ix, L.p. 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Michael Ackermann director, 10 percent owner 202 CARNEGIE CENTER, SUITE 109, PRINCETON NJ 08540
Rosemary A Crane director C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873